Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIMK2 | P53671 | 3/20 | 0.60 |
| ▸ | PDGFRB | P09619 | 7/20 | 0.56 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.55 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 2/20 | 0.49 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4107664 | 0.90 | PDGFRB (0.66) | PDGFRBP2RY12ALDH1A1RAB9AMAPK1 | |
| SCHEMBL8152759 | 0.87 | PI4KB (0.66) | LIMK2PDGFRBPI4KBP2RY12ALDH1A1 | |
| SCHEMBL3930200 | 0.86 | LIMK2 (0.54) | LIMK2PDGFRBPI4KBP2RY12ALDH1A1 | |
| SCHEMBL3919141 | 0.84 | LIMK2 (0.58) | LIMK2PDGFRBPI4KBP2RY12ALDH1A1 | |
| SCHEMBL4101122 | 0.84 | LIMK2 (0.56) | LIMK2PDGFRBPI4KBP2RY12ALDH1A1 | |
| SCHEMBL4113876 | 0.83 | KIT (0.55) | LIMK2PDGFRBPI4KBP2RY12ALDH1A1 | |
| SCHEMBL8149578 | 0.83 | LIMK2 (0.55) | LIMK2PDGFRBPI4KBP2RY12ALDH1A1 | |
| SCHEMBL8156268 | 0.83 | LIMK2 (0.54) | LIMK2PDGFRBPI4KBP2RY12ALDH1A1 | |
| SCHEMBL8149845 | 0.83 | LIMK2 (0.56) | LIMK2PDGFRBPI4KBP2RY12ALDH1A1 | |
| SCHEMBL8152854 | 0.83 | PI4KB (0.56) | LIMK2PDGFRBPI4KBP2RY12ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264415-A2 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | 4 AZA IP NV (BE) | 2009-10-22 | — | — | US | claimed |
| US-20090036430-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | 4 AZA IP NV (BE) | 2009-02-05 | — | — | US | claimed |
| WO-2009003669-A2 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | 4 AZA IP NV (BE) | 2009-01-08 | — | — | WO | claimed |
| US-20090264415-A2 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | 4 AZA IP NV (BE) | 2009-10-22 | — | — | US | disclosed |
| US-20090036430-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | 4 AZA IP NV (BE) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036430-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | PNPO, TYMP, PNP | LIMK2 2948/4885PDGFRB 199/4885PI4KB 2347/4885 |
| US-20090264415-A2 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | PNPO, TYMP, PNP | LIMK2 2948/4885PDGFRB 199/4885PI4KB 2347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.